Physician profile
Joel Grubbs
NPI 1649347501
$7,043.93
in general payments reported to CMS, 2019-2025
35 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $398 · 2021: $258 · 2022: $1,302 · 2023: $1,303 · 2024: $1,219 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,630.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,170.58 | 2019-2025 | |
| Abbvie INC. | $1,091.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $648.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $562.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $560.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $522.70 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.47 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $328.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $282.26 | 2019-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Corium, LLC | $228.97 | 2022-2024 | Azstarys |
| Sanofi-Aventis U.S. LLC | $136.29 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $120.57 | 2022 | |
| Idorsia Pharmaceuticals US INC | $105.97 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $104.06 | 2023-2025 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $86.34 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $72.01 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $70.91 | 2022-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $58.69 | 2020-2022 | |
| Shire North American Group INC | $56.39 | 2019 | |
| Almatica Pharma LLC | $51.61 | 2022-2024 | Loreev Xr |
| Aimmune Therapeutics, INC. | $51.45 | 2025 | Zenpep |
| Antares Pharma, INC. | $51.21 | 2024-2025 | Xyosted |
| Sumitomo Pharma America, INC. | $43.73 | 2024 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $38.10 | 2019-2020 | |
| Axsome Therapeutics, INC. | $36.02 | 2025 | Symbravo |
| Genentech USA, INC. | $36.01 | 2019-2021 | |
| Nevro Corp. | $25.30 | 2023 | Senza |
| Lundbeck LLC | $23.93 | 2024 | Rexulti |
| Amarin Pharma, INC. | $20.49 | 2022 | |
| Astellas Pharma US INC | $18.66 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $17.22 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.75 | 2025 | Rexulti |
| Adlon Therapeutics L.P. | $14.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Grubbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.